Department of Skin and Venereal Diseases, University of Ioannina Medical School, Ioannina, Greece.
Clin Exp Dermatol. 2009 Dec;34(8):e914-6. doi: 10.1111/j.1365-2230.2009.03697.x.
Although a reversible, sometimes severe, drug-induced thrombocytopenia is a recognized adverse drug reaction (ADR) in patients with psoriasis treated with efalizumab, definite proof for the association of thrombocytopenia with efalizumab is still lacking (currently level II evidence for ADR). We report a patient with psoriasis who had two episodes of reversible thrombocytopenia during efalizumab; the first occurred 5 months after introduction of the medication and the second 4 months after re-introduction of efalizumab for relapsing psoriasis. The development of a second episode of thrombocytopenia on re-exposure to efalizumab provides, for the first time in the literature to our knowledge, definite (level I) ADR evidence for efalizumab-induced thrombocytopenia.
虽然在接受依氟鸟氨酸治疗的银屑病患者中，可逆的、有时严重的药物诱导性血小板减少症是一种公认的药物不良反应（ADR），但仍缺乏血小板减少症与依氟鸟氨酸之间关联的明确证据（目前为 ADR 的 II 级证据）。我们报告了一名银屑病患者，在接受依氟鸟氨酸治疗期间发生了两次可逆性血小板减少症；第一次发生在用药 5 个月后，第二次发生在因银屑病复发重新使用依氟鸟氨酸 4 个月后。在重新接触依氟鸟氨酸时发生第二次血小板减少症发作，首次在文献中为我们所知，为依氟鸟氨酸引起的血小板减少症提供了明确的（I 级）ADR 证据。
